Sofosbuvir/Sofosbuvir API

Name	Sofosbuvir/Sofosbuvir
Chinese name	索磷布韦/索非布韦
Cas Number	1190307-88-0
Source	India
Qualifications	-/-/-/-/-

Sofosbuvir is the first specific HCV nucleotide analogue NS5B polymerase inhibitor (400 mg) developed by Pharmasset and Gilead. The drug was approved for marketing in the United States in December 2013, and was launched in more than a dozen European countries including Germany in January 2014. It was launched in China in September 2017. Sofosbuvir is effective against all 6 genotypes of HCV. Sofosbuvir only needs to be taken orally once a day, with few drug interactions and relatively few reports of adverse reactions. In 2016, the World Health Organization's hepatitis C guidelines recommended that sofosbuvir and dacatavir should be combined to treat HCV types 1, 3 and 4, and sofosbuvir should be combined with Harvoni to treat genes 1, 4, and 5. And type 6 HCV, combined with ribavirin for the treatment of gene types 2 and 3.

Hot Tags: sofosbuvir/sofosbuvir api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Aprepitant Aprepitant API, Bemeprost API, Valganciclovir Hydrochloride API, Paliperidone API, Gabapentin API, Linagliptin API

• Previous: Vilanterol Triphenylacetate API
• Next: Gadobutrol API